Back to News
Market Impact: 0.35
Galderma's Nemluvio Shows Sustained Three-Year Benefits In Atopic Dermatitis
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Galderma reported three-year ARCADIA long-term extension data showing Nemluvio (nemolizumab) delivered sustained improvements in skin lesions, itch, sleep disturbance and quality of life among adults and adolescents with moderate-to-severe disease. The durable clinical-results update is positive for Nemluvio's treatment profile and Galderma's dermatology growth outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
GALD0.72
More News
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- Why is Nidec stock plunging today?
- Nidec Corp shares slump after auditor declines to sign off on earnings
- We're raising our Micron price target after an incredible quarter and robust guidance
- Why is Kioxia stock rallying today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework